Sirtris Pharmaceuticals Inc. (SIRT) is in the Pharma Industry

• Sort by
• View Related Content by Tag

• Glaxo Profits Fall as Avandia and Generics Weigh

  By Ben Hirschler LONDON (Reuters UK) - GlaxoSmithKline GSK profits fell 5 percent in the first quarter, hit by tumbling sales of diabetes drug Avandia and generic competition to other products, the world's second biggest drugmaker said. The decline was less than analysts had feared, helped...

  News items 2008-04-23

  Tags: Performance, Analyst, Avandia, Sales, AstraZeneca Plc., Glaxo, GlaxoSmithKline Plc., Noven Pharmaceuticals Inc., Pfizer Inc., Sirtris Pharmaceuticals Inc., US

• Glaxo Profit Fall as Generics Weigh

  By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline Plc GSK profits fell 5 percent in the first quarter, hit by tumbling sales of diabetes drug Avandia and generic competition to other products, the world's second biggest drugmaker said. The decline was less than analysts...

  News items 2008-04-23

  Tags: Sales strategy, Sales force management, GlaxoSmithKline Plc., drug company, Security Incident Response Team, pharmaceutical company, sales, vaccine, Thomson Reuters Corp., London, analyst, wine, performance, earnings per share, operating profit, patient, acquisition, indu

• Glaxo to Buy Biotech Sirtris in $720 Mln Deal

  By Ransdell Pierson NEW YORK (Reuters UK) - GlaxoSmithKline GSK said on Tuesday it had agreed to buy biotechnology company Sirtris Pharmaceuticals Inc SIRT for $720 million (360.69 million pounds) in cash, in hopes its medicines that modulate an aging-related family of enzymes will be...

  News items 2008-04-22

  Tags: Glaxo, Type 2, Regulus, Biotechnology, Alnylam Pharmaceuticals Inc., GlaxoSmithKline Plc., Isis Pharmaceuticals Inc., Sirtris Pharmaceuticals Inc.

Additional Resources

• GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals

  LONDON, May 2 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc GSK announced today that Fountain Acquisition Corporation, a wholly-owned subsidiary of GSK, is commencing a cash tender offer to purchase all outstanding shares of common stock of Sirtris Pharmaceuticals, Inc. Sirtris, for $22.50 in cash without interest and less any required...

  Articles 2008-05-02

• Sirtris Pharmaceuticals Reports First Quarter 2008 Financial Results

  CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that it reported its consolidated financial results for the quarter ended March 31, 2008. First Quarter 2008 Financial Results Unaudited ...

  Articles 2008-05-01

• Bio-IT World Announces Winners of Its 2008 Best Practices Awards

  Bio-IT World magazine today announced thewinners of its fourth Best Practices Awards program. Grand Prize winnerswithin seven life sciences awards categories include Applied Biosystems,Christian-Albrechts-University, Eli Lilly & Company, GlaxoSmithKline,Genstruct, Sirtris Pharmaceuticals, AstraZeneca, and Merck & Company. Established in 2003, Bio-IT World's Best Practices Awards Programrecognizes these organizations for their...

  Articles 2008-04-30

• Genstruct and Sirtris Pharmaceuticals Win Bio-IT World's Best Practices Award

  Causal Network Modeling Provides Powerful Approach to Modeling Complex Biological Systems for Type 2 Diabetes CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better understand large scale biology, today announced that its joint collaboration...

  Articles 2008-04-30

• Hercules Technology Expects Realized Gain from the Announced Acquisition of Sirtris Pharmaceuticals, Inc. by GlaxoSmithKline

  Realized gain underlines Hercules' continued liquidity amid uncertain market conditions PALO ALTO, Calif. -- Hercules Technology Growth Capital, Inc. (NASDAQ:HTGC), the premier specialty finance company providing venture debt and equity to venture capital and private equity backed technology and life science companies at all stages of development, today...

  Articles 2008-04-24

• BellwetherReport.com Initiates Analyst Coverage on BRCM, ANAD, SIRT and REST

  BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have scheduled interviews with a number of...

  Articles 2008-04-23

• Glaxo in $720m deal for US enzyme research biotech

  Business News IN BRIEF *GlaxoSmithKline, the UK's biggest drug maker, is paying $720m for an early-stage US biotech company that promises to unlock the secrets of ageing. Sirtris Pharmaceuticals, based in Cambridge, Massachusetts, is working on sirtuins, a recently discovered type of enzyme linked to the ageing...

  Articles 2008-04-23

• GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in 'Sirtuin' Research and Development

  LONDON, PHILADELPHIA AND CAMBRIDGE, Mass., April 22 /PRNewswire-FirstCall/ -- GlaxoSmithKline and Sirtris Pharmaceuticals Incorporated announced today that they have entered into a definitive agreement pursuant to which GlaxoSmithKline will acquire Sirtris Pharmaceuticals for approximately USD720 million (or approx. GBP362 million) through a cash tender offer of USD22.50...

  Articles 2008-04-22

• Sirtris Announces SRT501 Lowers Glucose in Twice-Daily Dosing Clinical Trial; Study Suggests Dose Response for Proprietary Formulation of Resveratrol in Type 2 Diabetics

  Clinical Trial Further Demonstrates Efficacy of SIRT1 Activation In Humans CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, today announced positive top-line data from its twice-daily dosing...

  Articles 2008-04-17

• Sirtris Scientific Advisory Board Co-Chairs Publish First In-Vivo Data Showing SIRT1 Enzyme Can Suppress Tumor Development

  CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced that a research team led by the company's two Scientific Advisory Board co-chairs has demonstrated that overexpression of the SIRT1 enzyme can suppress tumor formation...

  Articles 2008-04-16

• Sirtris Receives Orphan Drug Designation from U.S. Food and Drug Administration for Resveratrol in Mitochondrial Disorder, MELAS Syndrome

  CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced that the United States Food and Drug Administration has granted the company orphan-drug designation for resveratrol in the treatment of MELAS syndrome (Mitochondrial myopathy, encephalopathy,...

  Articles 2008-04-02

• Sirtris Pharmaceuticals Presents at American Chemical Society April 7

  CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced that it will be presenting at the American Chemical Society annual meeting in New Orleans on Monday, April 7 at...

  Articles 2008-04-01

• Sirtris Pharmaceuticals Scientific Advisor Shows SIRT1 Activation Improves Huntington's Disease In Preclinical Model

  Presentations Will Take Place at the Pasteur Institute, March 28 and the British Societies for Cell and Developmental Biology at the University of Warwick, March 31 CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases...

  Articles 2008-03-28

• Sirtris Pharmaceuticals Announces the Appointment of Paul A. Friedman, M.D., President and CEO of Incyte Corporation, to its Board of Directors

  CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that Paul A. Friedman, M.D., President and CEO of Incyte Corporation, has been appointed to its Board of Directors....

  Articles 2008-03-25

• Sirtris Pharmaceuticals Presents at Future Leaders in the Biotechnology Industry Conference March 27

  CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced that it will be presenting at the BioCentury/Thomson Financial 15th Annual Future Leaders in the Biotechnology Industry Conference on Thursday,...

  Articles 2008-03-24

• Sirtris Announces First U.S. Patent Issued On Class of SIRT1 Activators; Patent Covers First NCE to Enter Human Clinical Trials

  CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that the United States Patent Office issued to Sirtris the first patent covering a broad class of compounds that...

  Articles 2008-03-19

• Sirtris Pharmaceuticals, Inc. Presents at Cowen and Companys 28th Annual Health Care Conference on March 18, 2008.

  M2 PRESSWIRE-14 March 2008-investorIM: Sirtris Pharmaceuticals, Inc. Presents at Cowen and Companys 28th Annual Health Care Conference on March 18, 2008C1994-2008 M2 COMMUNICATIONS LTD RDATE:14032008 InvestorIM has been created as a tool for the average investor. The idea is...

  Articles 2008-03-14